Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
|Articles|October 25, 2011
Gateway 2011: Sensient Pharmaceutical Coating Systems
Advertisement
Sensient® Pharmaceutical Coating Systems is a global leader in superior coating systems, brand-defining color solutions, and enhanced product performance for the pharmaceutical and nutraceutical markets. A single source for complete coating and visual enhancement solutions, we’re committed to innovation not only in our superior products and solutions but also in our personalized, responsive service.
Sensient Pharmaceutical Coating Systems leads the industry in the development and manufacture of innovative coatings and colors for the pharmaceutical and nutraceutical industries. Our coatings, excipients, and imprint inks offer visual and functional attributes necessary for brand definition, product identification, and trademark protection. Please visit us at AAPS 2011 at Booth #1419.
Sensient Pharmaceutical Coating Systems
2515 N. Jefferson, St. Louis, MO 63106
Phone: 800.325.8110
E-mail:
URL:
Advertisement
Related to this article
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Advertisement
Advertisement